Sign in now to see personalised content appear here.

You can also see your reading history and subscription details on your subscriber page.

Why subscribe?
Find out more.

Sign up for your FREE email newsletter  +


SymCel’s technology opens up new research avenues in oncology, diagnostics and anti-tumour drug development

CalScreener assay provides increased throughput to detect tumorous micro tissues, bacteria and parasitic worms

Europe | R and D | Measurement and Analysis

UK continues to lag behind other countries in access to new medicines, finds report

Life Science Competitiveness Indicators compare performance of UK on global life science stage


The many benefits of implementing used equipment strategies

The availability of high-quality surplus equipment is increasing at the same time that CDMOs are expanding to meet growing demand. Matt Hicks, COO, Federal Equipment Company, discusses the benefits of strategies to manage used equipment

Manufacturing and Equipment

Horizon Pharma to purchase Hyperion Therapeutics for US$1.1bn

Expands orphan drug business with the addition of two treatments for rare metabolic conditions

Europe | North America | Finance

Pieris Pharmaceuticals and the University of Melbourne receive grant

To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics

R and D

Quantitative Western blotting for monitoring biopharma production

Western blotting methods have changed little in 30 years. But this technique has traditionally been restricted by issues of variability. Mats Falk, GE Healthcare Life Sciences, argues that new technologies and detection techniques herald a new era

Biotechnology | Measurement and Analysis

Designing optimised, site-specific ADCs

Antibody-drug conjugates have provided a breakthrough in targeted medicines but ways of increasing their stability and efficacy are still required. Catalent highlights how these goals can be achieved using its SMARTag technology platform to produce site-specific ADCs

R and D

Navigating supply chains in a tightly regulated world

To meet changing business models and complex regulation, Diane Palmquist, VP, Manufacturing Industry Solutions at GT Nexus argues that supply chain visibility has to see fundamental change too

Information Technology

Frost & Sullivan expects development and commercialisation of antibacterial drugs to accelerate

Generating Antibiotic Incentives Now (GAIN) Act is expected to reduce barriers to market entry

Europe | North America

Alzheimer’s drug development: Time for a regulatory rethink?

At a recent EMA workshop held in London to discuss the lack of progress on Alzheimer’s therapies, drug developers highlighted the hurdles faced in meeting standards for drug approval

Europe | Regulatory | R and D | Therapeutic Sector